Exenatide for the treatment of weight gain associated with olanzapine in obese adults

[1] [2] GLP-1 medications work through several complementary mechanisms: Enhancing insulin secretion : They stimulate the pancreas to release insulin when blood glucose levels are elevated, helping to lower blood sugar in a glucose-dependent manner Suppressing glucagon release : They reduce the secretion of glucagon, a hormone that raises blood glucose, thereby preventing excessive glucose production by the liver Slowing gastric emptying : They delay the rate at which food leaves the stomach, leading to more gradual glucose absorption and increased feelings of fullness Reducing appetite : They act on areas of the brain involved in appetite regulation, helping to decrease food intake [2] [22] Commonly prescribed GLP-1 receptor agonists in the UK include semaglutide (Ozempic for diabetes, Wegovy for weight management, Rybelsus as an oral formulation), dulaglutide (Trulicity), liraglutide (Victoza for diabetes, Saxenda for weight management), and exenatide (Byetta, Bydureon)

This represented a 30% increased risk of osteoporosis among patients taking GLP-1s
Weight loss changes your levothyroxine dose requirements Levothyroxine dosing is weight-based
Key takeaway: Patients dont just want to lose weight
Many GLP-1 medications, such as Ozempic, Wegovy, Zepbound, and Saxenda, have been linked to digestive side effects